The last seven days were filled with dilutive offers, as biotechs seek to raise cash off the backs of their shareholders. However, it comes with the territory of the space, as these small-cap companies generally burn through cash trying to fund the next blockbuster drug with limited sources of financing available to them. Of course, that doesn't make it any better when dilution comes to your doorstep. Motley Fool health-care analyst David Williamson takes a closer look at Trius (UNKNOWN:TSRX.DL), and what the company's capital raise means for investors and the stock going forward.
The relevant video segment can be found between 0:00 and 3:45.